Focus Partners Wealth Acquires 551,274 Shares of Pfizer Inc. $PFE

Focus Partners Wealth boosted its stake in Pfizer Inc. (NYSE:PFE) by 39.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,965,615 shares of the biopharmaceutical company’s stock after purchasing an additional 551,274 shares during the period. Focus Partners Wealth’s holdings in Pfizer were worth $50,072,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. United Bank raised its holdings in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Foundations Investment Advisors LLC raised its holdings in Pfizer by 1.4% during the 2nd quarter. Foundations Investment Advisors LLC now owns 76,044 shares of the biopharmaceutical company’s stock worth $1,843,000 after purchasing an additional 1,081 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its position in shares of Pfizer by 14.6% in the 2nd quarter. Avantax Advisory Services Inc. now owns 423,497 shares of the biopharmaceutical company’s stock worth $10,266,000 after purchasing an additional 54,086 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.1%

Shares of NYSE PFE opened at $26.61 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $151.28 billion, a PE ratio of 19.56 and a beta of 0.47. The company’s fifty day simple moving average is $26.53 and its 200 day simple moving average is $25.54. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm posted $0.63 earnings per share. The business’s revenue was down 1.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.